Dr. Won Seog Kim is a distinguished leader in hematology and oncology, currently serving as Professor in the Division of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine. He earned his PhD in Medicine from Seoul National University College of Medicine following his master's degree from the same institution, establishing a robust academic foundation for his clinical career. After completing his internship and residency at Seoul National University Hospital, he pursued specialized fellowship training in medical oncology at both Seoul National University Hospital and Samsung Medical Center. His professional trajectory demonstrates remarkable progression within Samsung Medical Center, advancing from staff physician in 1997-1998 to full-time lecturer, assistant professor, associate professor, and ultimately to his current professorship since 2010.
Dr. Kim has established himself as a preeminent authority in lymphoma research and clinical management, with particular expertise in T-cell lymphoma subtypes. His groundbreaking work includes establishing the Samsung Medical Center-Lymphoma Cohort Study, which aims to develop predictive models for treatment outcomes and morbidity risks in lymphoma patients. As Chairman of the Consortium for Improving Survival of Lymphoma (CISL) and founding member of the Asian Lymphoma Study Group (ALSG), he has spearheaded multinational collaborative efforts to enhance lymphoma treatment protocols across the Asia-Pacific region. His research contributions have significantly advanced clinical understanding of lymphoma biology and treatment response, with numerous publications in high-impact hematology journals shaping contemporary treatment approaches for this complex disease.
Beyond his direct research contributions, Dr. Kim has assumed pivotal leadership roles that have transformed the landscape of lymphoma care in Korea and internationally. As Chairman of the lymphoma working party of the Korean Society of Hematology and Co-Chair of the T-cell Lymphoma Forum (TCLF), he has been instrumental in developing standardized treatment guidelines and fostering collaborative research networks. His editorial contributions and mentorship have cultivated a new generation of hematologist-oncologists committed to advancing lymphoma research. Currently, Dr. Kim continues to drive innovation in lymphoma therapeutics through participation in clinical trials investigating novel agents like golidocitinib for relapsed or refractory peripheral T-cell lymphoma. His ongoing work promises to further refine precision medicine approaches for lymphoma patients while strengthening international research collaborations to improve survival outcomes globally.
